Medicaments
First Claim
1. A pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant, with the proviso that when said formulation consists essentially of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:
- 7900 (0.866%).
0 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to aerosol formulations of use for the administration of medicaments by inhalation, in particular a pharmaceutical aerosol formulation which comprises particulate salbutamol and physiologically acceptable salts and solvates thereof and a fluorocarbon or hydrogen-containing chlorofluorocarbon propellant, which formulation is substantially free of surfactant. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation as defined is also described.
60 Citations
17 Claims
-
1. A pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant, with the proviso that when said formulation consists essentially of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:
- 7900 (0.866%).
- View Dependent Claims (9, 10, 11, 12, 13)
-
2. A pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant, with the provisos that when said formulation consists essentially of salbutamol and 1,1,1,2-tetrafluoroethane in a weight ratio of 0.05:
- 18, said salbutamol is present in the form of a physiologically acceptable salt and when said formulation consists essentially of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69;
7900 (0.866%).
- 18, said salbutamol is present in the form of a physiologically acceptable salt and when said formulation consists essentially of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69;
-
3. A pharmaceutical aerosol formulation consisting essentially of a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, with the proviso that when said formulation consists essentially of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:
- 7900 (0.866%).
-
4. A pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant, and wherein the salbutamol or a physiologically acceptable salt or solvate thereof is present in an amount of less than 0.866% w/w based on the total weight of the formulation.
-
5. A pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant, and wherein the salbutamol or a physiologically acceptable salt or solvate thereof is present in an amount of 0.005 to 0.594% w/w based on the total weight of the formulation.
-
6. A pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant, and wherein the salbutamol or a physiologically acceptable salt or solvate thereof is present in an amount of 0.005 to 0.264% w/w based on the total weight of the formulation.
-
7. A pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant, and wherein the salbutamol or a physiologically acceptable salt or solvate thereof is present in an amount of 0.005 to 0.174% w/w based on the total weight of the formulation.
-
8. A pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant, and wherein the weight ratio of salbutamol or a pharmaceutically acceptable salt or solvate thereof to propellant is less than 0.05:
- 18.
-
14. A canister suitable for delivering a pharmaceutical aerosol formulation which comprises a container capable of withstanding the vapour pressure of the propellant used, which container is closed with a metering valve and contains a pharmaceutical aerosol formulation which comprises a physiologically effective amount of particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant and with the proviso that when said formulation consists essentially of salbutamol or salbutamol sulphate and 1,1,1,2-tetrafluoroethane the weight to weight ratio of medicament to propellant is other than 69:
- 7900 (0.866%).
- View Dependent Claims (15, 16)
-
17. A method of treating respiratory disorders which comprises administration by inhalation of an effective amount of a pharmaceutical aerosol formulation which comprises particulate salbutamol or a physiologically acceptable salt or solvate thereof and 1,1,1,2-tetrafluoroethane as propellant, which formulation is substantially free of surfactant.
Specification